ClinicalTrials.gg
RecruitingNCT06833684MOTIONUpdated Jan 22, 2026

MowOot and Trans-anal Irrigation fOr coNstipation

An interventional study of ICE Treatment and TAI Standard-of-Care Treatment in Constipation Chronic Idiopathic, sponsored by usMIMA S.L.. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by usMIMA S.L. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 61 studies in Constipation with a site in United Kingdom — 4 open to participants now, 5 under way, none of them phase 3. Constipation · United Kingdom.

Planned enrollment
36th of 54
40 · median 93
Started
2025
with 2 others
No phase
23 of 61
2 open now
Registered
57th of 61
by date
Lead sponsor
3 of 61
usMIMA S.L.

Among the 61 studies in Constipation with a site in United Kingdom, this one is the 36th largest by planned enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2025, is one of 23 with no phase, and was the 57th registered.

Constipation

1,048 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

4 of the 61 studies in Constipation with a site in United Kingdom are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Constipation with a site in United Kingdom, or all of them as a file.
02

Study summary

This prospective, open-labelled, longitudinal, controlled study aims to evaluate the suitability of Intermittent Colonic Exoperistalsis (ICE) treatment for adults with refractory chronic constipation who are awaiting trans-anal irrigation (TAI). The ICE treatment will be applied using the MOWOOT device (USMIMA). The study involves two treatment groups: an experimental group receiving daily ICE treatments and a control group following standard TAI care. Participants will serve as their own controls in pre- and post-treatment analyses to assess changes in bowel management satisfaction and other outcomes.

Read the detailed description

This study is a prospective, open-labelled, longitudinal, controlled trial conducted at a single center. It aims to assess the suitability of Intermittent Colonic Exoperistalsis (ICE) treatment for bowel management in adults with refractory chronic constipation who are awaiting trans-anal irrigation (TAI). The ICE treatment will be applied using the MOWOOT device (USMIMA). The study includes two treatment groups:

Experimental ICE Group: Participants will receive one ICE treatment session lasting 20 minutes daily, at the same hour, for 12 weeks.

Control TAI Group: Participants will follow the usual TAI standard-of-care treatment for 12 weeks.

Participants will be given the option to choose between the ICE treatment and the TAI treatment after both options are explained to them. Healthcare professionals will recommend the most suitable treatment based on individual patient needs, but the final decision will rest with the patients.

The primary objective is to evaluate the change in satisfaction with daily quality of life related to bowel management, measured by a Likert scale (Bothersome scale). Secondary objectives include assessing the efficacy of the ICE treatment on chronic constipation, both qualitatively and quantitatively, and evaluating the economic impact from the hospital's perspective.

Secondary outcomes will be measured through various patient-reported and health professional-reported metrics, including changes in quality of life (PAC-QOL), constipation symptoms (PAC-SYM), constipation severity (CCCS), time spent in bowel management and evacuation, use of other treatments, number of consultations and hospital admissions, productivity, acceptability and ease of use of the ICE treatment, reported problems, compliance, adherence, and persistence in treatment. Health professional outcomes will include time spent per visit, total time spent until independent use of MOWOOT, ease of patient management, and patient treatment preferences.

03

Conditions studied

  • Constipation Chronic Idiopathic

Browse trials for

Keywords

  • constipation
  • transit problems
  • Trans-Anal Irrigation
  • Intermittent Colonic Exoperistalsis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult people (18 yo or older) of any gender
  2. Attending their pre-scheduled on-site visit to the site (The Sir Alan Parks Physiology \& Pelvic Floor Biofeedback Unit \| Central Middlesex Hospital) due to constipation (Symptoms meeting the American College of Gastroenterology definition of chronic constipation: unsatisfactory defaecation characterized by infrequent stool, difficult stool passage or both for at least previous 3 months.
  3. Bothered by their constipation
  4. Failed biofeedback (in absence of outlet problems)
  5. In waiting list to use TAI
  6. Able to undertake the treatment with the MOWOOT device or TAI themselves, or with a carer willing to do it
  7. Able to understand the study requirements
  8. Able to understand written and spoken English (due to questionnaire validity)
  9. Able and willing to provide written to participate

Exclusion criteria

Exclusion Criteria:

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

Disease phenotype exclusion criteria:

  • Irritable Bowel Syndrome with Diarrhoea (IBS-D) or alternating constipation and diarrhoea (IBSmix): (not due to laxative use)
  • Inflammatory Bowel Disease (IBD)
  • Significant outlet problem
  • Trapping rectocele
  • Intra anal rectal intussusception
  • External rectal prolapse

Device-related exclusion criteria:

  • Abdominal perimeter ≤65cm or ≥130cm
  • Unable to independently use the MOWOOT technology, unless a carer is available daily to assist

Other medical conditions, medications and :

  • Pregnancy or attempt to become pregnant in the next 6 months.
  • Previous large bowel resection
  • Active anorexia or bulimia
  • Active abdominal cancer
  • Large inguinal or umbilical hernia
  • Recent abdominal scars, abdominal wounds or skin disorders that may make abdominal massage uncomfortable
  • Any condition that contraindicates abdominal massage.
  • Significant abdominal pain
  • Participation in another parallel interventional clinical trial or less than 2 months from participation in a previous interventional clinical trial
  • Planned surgery* if it might be within trial dates (* minor surgery not affecting adherence to treatment is allowed)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Experimental ICE Group

    Each patient will receive 1 ICE treatment of 20 minutes at least once per day, every day at the same hour, during the intervention period of 12 weeks.

    Device: ICE Treatment

  • Active comparator
    Control TAI Group

    Each patient will follow the usual TAI standard-of-care treatment for the intervention period of 12 weeks.

    Procedure: TAI Standard-of-Care Treatment

Interventions

  • DeviceICE Treatment

    Each patient in the Experimental ICE Group will receive one Intermittent Colonic Exoperistalsis (ICE) treatment session lasting 20 minutes. These sessions will be conducted at least once per day, every day at the same hour, for a total duration of 12 weeks. The ICE treatment involves using the MOWOOT medical device designed to alleviate chronic constipation by stimulating colonic peristalsis.

  • ProcedureTAI Standard-of-Care Treatment

    Each patient in the Control TAI Group will follow the usual Trans-Anal Irrigation (TAI) standard-of-care treatment. This involves the regular use of TAI procedures as prescribed by healthcare professionals for the intervention period of 12 weeks. The TAI treatment is a well-established method for managing chronic constipation by mechanically clearing the bowel.

06

What researchers measure

Primary outcomes

  1. Change in Satisfaction with Daily Quality of Life Related to Bowel Management

    Assessed by the Bothersome Scale (a Likert scale) where 0 is 'not at all' and 10 is 'a great deal,' with higher scores indicating a worse outcome

    Time frame: 12 weeks

Secondary outcomes

  1. Changes in Quality of Life According to PAC-QOL Score

    Assessed by the PAC-QOL (Patient Assessment of Constipation Quality of Life) scale, where higher scores indicate a worse quality of life.

    Time frame: 12 weeks

  2. Changes in Constipation Symptoms According to PAC-SYM Score

    Measured using the PAC-SYM (Patient Assessment of Constipation Symptoms) scale, with higher scores reflecting more severe constipation symptoms

    Time frame: 12 weeks

  3. Changes in Constipation Severity According to CCCS

    Evaluated by the CCCS (Constipation Clinical Severity Scale), where higher scores denote greater severity of constipation

    Time frame: 12 weeks

  4. Change in Time Spent in Bowel Management

    Measured in minutes per day, data from bowel diaries.

    Time frame: 12 weeks

  5. Change in Time Spent in Evacuation

    Measured in minutes per day, data from bowel diaries.

    Time frame: 12 weeks

  6. Change in Use of Other Treatments (e.g., Laxatives, Suppositories)

    Data from patient surveys.

    Time frame: 12 weeks

  7. Change in Number of Consultations to Primary Care (GP, Nurse)

    Data from patient surveys.

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
  • The Sir Alan Parks Physiology & Pelvic Floor Biofeedback Unit., Central Hospital, Department of Physiology, St Mark's Hospital, The National Bowel Hospital
    London, London NW10 7NS, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jul 2026, 13 months after the start.

Of 71 industry-sponsored interventional studies with no phase under Constipation, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 13 months is above that.

Counting every sponsor, half of 316 studies reached it within 14 months; a quarter within 6 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2025
First posted
Feb 19, 2025
StartActual
Jun 25, 2025
Primary completionEst.
Jul 31, 2026
CompletionEst.
Sep 1, 2026
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06833684
Lead sponsor
usMIMA S.L.
Responsible party
Sponsor
First posted
Feb 19, 2025
Start date
Jun 25, 2025
Primary completion
Jul 31, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Jan 22, 2026

Study contacts

Immaculada Herrero-Fresneda, PhD
Contact
ihf@mowoot.com
+34 935106653
Gregory Thomas, MD, PhD
principal investigator · The Sir Alan Parks Physiology & Pelvic Floor Biofeedback Unit | Central Middlesex Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion